Pembrolizumab plus enfortumab vedotin in urothelial cancer

Matteo Santoni¹, Hideki Takeshita², Francesco Massari^{3

4}, Aristotelis Bamias⁵, Linda Cerbone⁶, Ondrej Fiala^{7

8}, Veronica Mollica^{9

10}, Sebastiano Buti¹¹, Angela Santoni¹², Joaquim Bellmunt¹³

Affiliations

¹ Oncology Unit, Macerata Hospital, Macerata, Italy.
² Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
³ Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. fmassari79@gmail.com.
⁴ Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. fmassari79@gmail.com.
⁵ 2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
⁶ Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy.
⁷ Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
⁸ Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
⁹ Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
¹⁰ Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
¹¹ Medical Oncology Unit, University Hospital of Parma - Department of Medicin and Surgery, University of Parma, Parma, Italy.
¹² Department of Molecular Medicine, Sapienza University, Rome Italian Pasteur Institute, Cenci-Bolognetti Foundation, Rome, Italy.
¹³ Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

PMID: 38267716
DOI: 10.1038/s41585-024-00858-y

Pembrolizumab plus enfortumab vedotin in urothelial cancer

Matteo Santoni et al. Nat Rev Urol. 2024 Jul.

. 2024 Jul;21(7):387-388.

doi: 10.1038/s41585-024-00858-y.

Authors

Affiliations

¹ Oncology Unit, Macerata Hospital, Macerata, Italy.
² Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
³ Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. fmassari79@gmail.com.
⁴ Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. fmassari79@gmail.com.
⁵ 2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
⁶ Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy.
⁷ Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
⁸ Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
⁹ Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
¹⁰ Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
¹¹ Medical Oncology Unit, University Hospital of Parma - Department of Medicin and Surgery, University of Parma, Parma, Italy.
¹² Department of Molecular Medicine, Sapienza University, Rome Italian Pasteur Institute, Cenci-Bolognetti Foundation, Rome, Italy.
¹³ Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

PMID: 38267716
DOI: 10.1038/s41585-024-00858-y

No abstract available

PubMed Disclaimer

Cited by

Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives.
Kwon WA, Lee MK. Kwon WA, et al. Cancers (Basel). 2024 Dec 5;16(23):4078. doi: 10.3390/cancers16234078. Cancers (Basel). 2024. PMID: 39682263 Free PMC article. Review.
Two Cases of Revisional Urinary Diversion from Ureterocutaneostomy to Ileal Conduit: A Staged Urinary Diversion Strategy for Patients with Bladder Cancer in the Targeted and Immunotherapy Era.
Tanaka Y, Takeshita H, Yokota K, Chon S, Fujii K, Ishida A, Arai M, Tachibana K, Nagamoto S, Kitayama S, Okada Y, Yano A, Satoru K. Tanaka Y, et al. Am J Case Rep. 2025 Mar 7;26:e946924. doi: 10.12659/AJCR.946924. Am J Case Rep. 2025. PMID: 40051135 Free PMC article.
Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer.
Taylor C, Patterson KM, Friedman D, Bacot SM, Feldman GM, Wang T. Taylor C, et al. Cancers (Basel). 2024 Sep 4;16(17):3071. doi: 10.3390/cancers16173071. Cancers (Basel). 2024. PMID: 39272928 Free PMC article. Review.

References

1. Powles, T. B. et al. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann. Oncol. 34 (Suppl. 2), S1340 (2023). - DOI
1. Chikuma, S. et al. PD-1-mediated suppression of IL-2 production induces CD8+ T cell energy? in vivo. J. Immunol. 182, 6682–6689 (2009). - DOI - PubMed
1. Milella, M. et al. Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder. Br. J. Cancer 79, 770–779 (1999). - DOI - PubMed - PMC
1. Sakatani, T. et al. IFN-gamma expression in the tumor microenvironment and CD8-positive tumor-infiltrating lymphocytes as prognostic markers in urothelial cancer patients receiving pembrolizumab. Cancers 14, 263 (2022). - DOI - PubMed - PMC
1. Baker, S. C. et al. The urothelial transcriptomic response to interferon gamma: implications for bladder cancer prognosis and immunotherapy. Cancers 14, 5295 (2022). - DOI - PubMed - PMC

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Pembrolizumab plus enfortumab vedotin in urothelial cancer

Affiliations

Pembrolizumab plus enfortumab vedotin in urothelial cancer

Authors

Affiliations

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical